Business Context and Reporting Period
This Form 8-K is filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc., as indicated in the metadata) for the reporting period of October 19, 2009. The filing reports the entry into a material definitive agreement regarding a private placement offering of securities.
Key Financial Metrics and Transaction Details
The company entered into a Securities Purchase Agreement with five institutional investors. The transaction details are as follows:
- Securities Issued: 6,072,383 shares of common stock and warrants to purchase up to 2,125,334 shares of common stock.
- Warrant Terms: Initial exercise price of $1.00 per share; exercisable for five years from the date of delivery.
- Expected Net Proceeds: Approximately $4.7 million (after deducting placement agent fees and estimated offering expenses, excluding warrant exercise proceeds).
- Placement Agent Fees: Rodman & Renshaw, LLC will receive a fee equal to 6% of gross proceeds plus warrants to purchase 245,932 shares at $1.00 per share.
- Closing Date: Expected on or about October 23, 2009.
Note: This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics for the company's operations.
Material Changes
The primary material change is the execution of the Securities Purchase Agreement and the Engagement Letter with Rodman & Renshaw, LLC. This represents a new capital raise event rather than a change in operational performance compared to a prior period.
Guidance, Outlook, and Risks
Management Commentary: The offering is being made pursuant to a shelf registration statement on Form S-3 (Registration No. 333-152640) declared effective on August 8, 2008. A prospectus supplement is expected to be filed on or about October 21, 2009.
Risks and Contingencies: The closing of the offering is subject to the satisfaction of standard closing conditions. The filing incorporates by reference the full text of the Securities Purchase Agreement, Warrant form, and Engagement Letter for complete terms.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received, as the $4.7 million figure is an expectation.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and conditions.
- Confirm the dilution impact of the 6,072,383 new shares and the potential 2,125,334 warrant shares on existing shareholders.
- Check the press release (Exhibit 99.1) for any additional context on the use of proceeds.
- Ensure the prospectus supplement is filed as scheduled to validate the offering terms.